The synthesis of Aβ occurs through the breakdown of APP, by the enzyme named β-site amyloid precursor protein cleaving enzyme 1 (BACE-1), which is central to AD development, and thus is a main therapeutic target [23]. This evidence concerns the gene APP and Alzheimer disease.